Skip to content

Crossover Comparison of Tidal Volume Delivery During Nasal Intermittent Positive Pressure Ventilation in Preterm Infants: Infant Cannula vs. Nasal Continuous Positive Airway Pressure Prongs

Crossover Comparison of Tidal Volume Delivery During Nasal Intermittent Positive Pressure Ventilation in Preterm Infants: Infant Cannula vs. Nasal Continuous Positive Airway Pressure Prongs

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04326270
Enrollment
20
Registered
2020-03-30
Start date
2019-03-07
Completion date
2020-06-30
Last updated
2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome in Premature Infant

Keywords

nasal intermittent positive pressure ventilation, non-invasive ventilation, nasal continuous positive airway pressure prongs, infant nasal cannula, tidal volume

Brief summary

Crossover bedside clinical study to examine relative tidal volume delivery during nasal intermittent positive pressure ventilation (NIPPV) and directly compare the RAM® infant cannula to a nasal continuous positive airway pressure (nCPAP) delivery system in vivo. The study population will consist of preterm neonates with mild respiratory insufficiency who are receiving NIPPV, non-invasive neurally adjusted ventilatory assist (NIV NAVA), or nCPAP.

Detailed description

Bedside crossover study of neonates with mild respiratory distress receiving NIPPV. Infants serve as their own controls and are randomized to initial interface of either RAM® infant cannula or Miniflow® nCPAP prongs. Infants are instrumented with the following monitoring equipment: Edi orogastric tube to measure electrical activity of the diaphragm, transcutaneous monitor to measure transcutaneous CO2 and O2, pulse oximeter to measure heart rate and oxygen saturation, and respiratory inductance plethysmography (RIP) bands around the chest and abdomen to measure breathing movements and relative Vt (arbitrary units, a.u.). Data are continuously and simultaneously acquired using a data acquisition system. After 10 minutes of stabilization, infants receive 5 minutes of NIPPV on each of a sequence of four commonly used pressure settings (expressed as peak inspiratory pressure / positive end expiratory pressure): 16/5, 16/8, 20/5, 20/8. This sequence is not randomized and is constant between interfaces. Subjects are then placed on the alternate interface, and the sequence is repeated. Events (breaths) are separated into 3 types: patient effort synchronized with NIPPV breaths (type I), NIPPV breaths without patient effort (type II), and patient effort without NIPPV breaths (type III).

Interventions

DEVICENasal interface

Randomized to initial interface of nCPAP prongs or infant cannula

Sponsors

Arkansas Children's Hospital Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 28 Days
Healthy volunteers
No

Inclusion criteria

* Chronologic age less than 28 days * Gestational age at birth between 24 weeks 0 days to 34 weeks 6 days * Currently receiving NIPPV, NIV NAVA, or nCPAP

Exclusion criteria

* Oxygen requirement greater than 40% * Peak inspiratory pressure greater than 20 cm H2O * Major congenital anomalies of the heart or lungs

Design outcomes

Primary

MeasureTime frameDescription
Relative tidal volume delivery, breath type I1 hourRelative tidal volume measured in arbitrary units (AU) via RIP bands during synchronized breaths
Relative tidal volume delivery, breath type II1 hourRelative tidal volume measured in arbitrary units (AU) via RIP bands during ventilator-driven breaths
Relative tidal volume delivery, breath type III1 hourRelative tidal volume measured in arbitrary units (AU) via RIP bands during patient-driven breaths

Secondary

MeasureTime frame
Oxygen saturation1 hour
Ventilator pressure delivery1 hour
Transcutaneous oxygen tension1 hour
Transcutaneous carbon dioxide tension1 hour
Ventilator flow delivery1 hour
Heart rate1 hour

Countries

United States

Contacts

Primary ContactAshley Lynch, M.D.
allynch@uams.edu501-412-0988

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026